Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
NCT07108283 · View on ClinicalTrials.gov ↗
Study Summary
Vitiligo is a long-term autoimmune condition that causes the skin to lose its color. The body's germ-fighting system (immune system) mistakenly attacks the skin cells (melanocytes) which produce the pigment that gives the skin color (melanin). This leads to the formation of patches of skin with less or no pigment (depigmentation). These patches can occur anywhere on the body. In the nonsegmental form of vitiligo, similar patches occur on both sides of the body (symmetrical patches). The main aim of this study is to learn how safe zasocitinib is, how well it works and how well it is tolerated by adults with nonsegmental vitiligo. The participants will receive the study treatment (either zasocitinib or placebo) for up to 1 year (52 weeks). The placebo looks like the zasocitinib capsule but does not have any medicine in it. Participants who receive placebo at the beginning will change to zasocitinib after about 6 months. During the study, participants will visit their study clinic 11 times.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Zasocitinib
Study Locations (20)
California
- First OC Dermatology — Fountain Valley
- Center for Dermatology Clinical Research, Inc. — Fremont
- The Vitiligo & Pigmentation Institute of Southern California — Los Angeles
- UC Davis Department of Dermatology — Sacramento
- Therapeutics Clinical Research — San Diego
Florida
- Encore Medical Research of Boynton Beach LLC. — Boynton Beach
- San Marcus Research Clinic, Inc. — Miami Lakes
- Advanced Clinical Research Institute (ACRI) — Tampa
- Encore Medical Research of Weston LLC — Weston
New York
- Mount Sinai — New York
- Weill Cornell Medicine — New York
- Markowitz Medical dba Optiskin — New York
Louisiana
- DelRicht Research - Dermatology — Baton Rouge
- DelRicht Research (Audubon Dermatology) — New Orleans
Arkansas
- Dermatology Trial Associates — Bryant
Maryland
- Lawrence J Green LLC — Rockville
Michigan
- Hamzavi Dermatology - Canton — Canton
Ohio
- Bexley Dermatology (legal entity - Dermatologists of Southwestern Ohio, LLC) — Bexley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-11-03 |
| Est. Completion | 2027-11-09 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07108283
The ClinicalTrials.gov registry entry for NCT07108283 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 387 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Nonsegmental Vitiligo appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07108283 reports 20 study locations spanning 10 distinct geographic areas — top geographies include California, Florida, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07108283 about?
NCT07108283 is a clinical study titled "A Study of Zasocitinib in Adults With Nonsegmental Vitiligo". Vitiligo is a long-term autoimmune condition that causes the skin to lose its color. The body's germ-fighting system (immune system) mistakenly attacks the skin cells (melanocytes) which produce the pigment that gives the skin color (melanin). This leads to the formation of patches of skin with less...
What is the current status of trial NCT07108283?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-11-03. Estimated completion is 2027-11-09.
What conditions does trial NCT07108283 study?
This clinical trial studies the following conditions: Nonsegmental Vitiligo. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07108283?
The interventions under investigation include: Placebo (OTHER), Zasocitinib (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07108283?
This trial is sponsored by Takeda, which has 387 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07108283 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.